ID   NZM062
AC   CVCL_0D26
SY   NZM62
DR   cancercelllines; CVCL_0D26
DR   Wikidata; Q54931598
RX   PubMed=32567790;
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=32567790).
CC   Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790).
ST   Source(s): PubMed=32567790
ST   CSF1PO: 10
ST   D13S317: 10,12
ST   D21S11: 30,31
ST   D2S1338: 21
ST   D3S1358: 16,18
ST   D5S818: 12
ST   D7S820: 10
ST   FGA: 18,25
ST   vWA: 16
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_0D27 ! NZM064
CA   Cancer cell line
DT   Created: 10-04-15; Last updated: 19-12-24; Version: 8
//
RX   PubMed=32567790; DOI=10.1111/pcmr.12908; PMCID=PMC7818249;
RA   Tran K.B., Gimenez G., Tsai P., Kolekar S., Rodger E.J.,
RA   Chatterjee A., Jabed A., Shih J.-H., Joseph W.R., Marshall E.S.,
RA   Wang Q., Print C.G., Eccles M.R., Baguley B.C., Shepherd P.R.;
RT   "Genomic and signalling pathway characterization of the NZM panel of
RT   melanoma cell lines: a valuable model for studying the impact of
RT   genetic diversity in melanoma.";
RL   Pigment Cell Melanoma Res. 34:136-143(2021).
//